Therefore, although the DT‐2216 resistance in several T‐ALL cells is rare, the authors claim that its occurrence cannot be predicted based on measurement of BCL‐2 and MCL‐1 proteins, before and after treatment with PROTAC DT2216.184. Here, BCL2 is linked to acute lymphoblastic leukemia.